FRAMINGHAM, MA--(MARKET WIRE)--Jul 25, 2007 -- Symbollon Pharmaceuticals, Inc. (OTC BB:SYMBA.OB - News) today announced that the company has filed a new patent application covering IoGen(TM), its proprietary compound being evaluated for its ability to eliminate excess tissue growth in female reproductive organs.
